Q3 EPS Estimates for Haemonetics Lowered by Zacks Research

Haemonetics Co. (NYSE:HAE - Free Report) - Equities researchers at Zacks Research lowered their Q3 2025 earnings per share estimates for Haemonetics in a research report issued on Wednesday, November 27th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $1.19 per share for the quarter, down from their prior estimate of $1.22. The consensus estimate for Haemonetics' current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics' Q4 2025 earnings at $1.26 EPS, FY2025 earnings at $4.59 EPS, Q1 2026 earnings at $1.18 EPS, Q3 2026 earnings at $1.32 EPS, FY2026 earnings at $5.17 EPS and Q1 2027 earnings at $1.48 EPS.

Other equities research analysts have also issued reports about the company. Barrington Research reissued an "outperform" rating and set a $108.00 price target on shares of Haemonetics in a research note on Friday, November 8th. JMP Securities reaffirmed a "market outperform" rating and set a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. BTIG Research assumed coverage on Haemonetics in a report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 price target for the company. Bank of America assumed coverage on Haemonetics in a research report on Wednesday, September 11th. They issued a "neutral" rating and a $85.00 price target for the company. Finally, Raymond James upgraded Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price objective on the stock in a report on Friday, November 8th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $107.88.

Haemonetics Price Performance

NYSE HAE traded up $0.01 during trading on Monday, hitting $87.48. 525,220 shares of the stock traded hands, compared to its average volume of 554,700. The company has a market capitalization of $4.39 billion, a P/E ratio of 36.30, a price-to-earnings-growth ratio of 1.36 and a beta of 0.32. The firm has a 50-day simple moving average of $80.21 and a 200-day simple moving average of $82.00. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. Haemonetics has a 12-month low of $70.25 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.03. The firm had revenue of $345.50 million during the quarter, compared to analysts' expectations of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The firm's revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the business posted $0.99 earnings per share.

Institutional Trading of Haemonetics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC raised its stake in shares of Haemonetics by 3.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier's stock valued at $304,000 after purchasing an additional 117 shares in the last quarter. Vontobel Holding Ltd. lifted its position in shares of Haemonetics by 3.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier's stock valued at $392,000 after acquiring an additional 180 shares in the last quarter. QRG Capital Management Inc. lifted its position in Haemonetics by 6.9% in the 2nd quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier's stock worth $333,000 after buying an additional 260 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Haemonetics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier's stock valued at $1,176,000 after purchasing an additional 272 shares in the last quarter. Finally, Keene & Associates Inc. raised its holdings in shares of Haemonetics by 3.0% during the 3rd quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier's stock valued at $818,000 after purchasing an additional 298 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.